BG Medicine (BGMD)
BG Medicine Revenue Growth: -43.86%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BGMD Revenue Growth Rankings
| Overall | 2nd percentile | 4253 of 4358 |
| Sector | 5th percentile | 430 of 456 in Healthcare |
| Industry | 4th percentile | 24 of 25 in Medical Laboratories & Research |
BGMD Revenue Growth Range, Past 5 Years
| Minimum | -47.13% | Jun 2011 |
| Maximum | 722.1% | Mar 2011 |
| Average | 160.8% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these BGMD related companies
BGMD News
BG Medicine Obtains CE Mark and Files 510(k) for Expanded BGM Galectin-3 Indication
May 15, 6:48AM Benzinga
May 15, 6:48AM Benzinga
BG Medicine, Inc. Obtains CE Mark and Files 510(k) for Expanded BGM Galectin-3(TM) Indication
May 15, 6:45AM GlobeNewswire
May 15, 6:45AM GlobeNewswire
BG Medicine Announces Publication of First Study on Use of Galectin-3 in Selection of Drug Therapy in Heart Failure
May 14, 8:15AM GlobeNewswire
May 14, 8:15AM GlobeNewswire
BG Medicine, Inc. Announces Availability of Galectin-3 Diagnostic Testing Through Mayo Medical Laboratories
May 14, 8:00AM GlobeNewswire
May 14, 8:00AM GlobeNewswire
BG Medicine Announces First Quarter 2012 Financial Results Release Date and Conference Call Information
May 09, 8:00AM GlobeNewswire
May 09, 8:00AM GlobeNewswire
$BGMD filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3aUH
about 27 days ago by MarketBrief
about 27 days ago by MarketBrief
$BGMD forms bullish "Continuation Wedge" chart pattern. http://stks.co/2tRw
about 73 days ago by RecogniaEvents
about 73 days ago by RecogniaEvents
BG Medicine, Inc. (BGMD) Posts Q4 Loss of 23c/Share, Narrower than Views
Mar 08, 7:07AM Street Insider
Mar 08, 7:07AM Street Insider
Ladenburg Thalmann Maintains BG Medicine at Buy, Raises PT from $8.25 to $16.5
Feb 14, 8:32AM Benzinga
Feb 14, 8:32AM Benzinga
BG Medicine, Inc. Secures $15 Million Loan Facility From GE Capital and Comerica
Feb 13, 7:50AM Benzinga
Feb 13, 7:50AM Benzinga
BG Medicine, Inc. to Host Investor and Analyst Briefing and Webcast on February 13, 2012 in New York City
Feb 07, 8:30AM GlobeNewswire
Feb 07, 8:30AM GlobeNewswire
BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Jan 13, 4:10PM GlobeNewswire
Jan 13, 4:10PM GlobeNewswire
BG Medicine $BGMD IPO trading at $7.27 after pricing at $7, which was down from $13-$15 range.
about 479 days ago by Street_Insider
about 479 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BGMD | 4.30 | +0.14 | +3.37% | 83.72M |
| BGFV | 6.35 | -0.01 | -0.16% | 138.11M |
| BGCP | 6.21 | +0.02 | +0.32% | 861.14M |
| BGC | 29.51 | +0.07 | +0.24% | 1.468B |
| BG | 61.06 | +0.57 | +0.94% | 8.896B |
| BEST | 0.2665 | +0.01 | +2.62% | 7.339M |
| BERK | 7.68 | -0.25 | -3.15% | 110.90M |
| BEN | 106.79 | -1.21 | -1.12% | 23.06B |
| BELFB | 16.77 | -0.31 | -1.81% | 36.39M |
| BELFA | 17.70 | -0.68 | -3.70% | 209.04M |
